N

Natera

NTRA

102.970
USD
0.58
(0.57%)
Market Closed
Volume
26,604
EPS
0
Div Yield
0
P/E
-49
Market Cap
14,833,114,140
Related Instruments
A
ABUS
0.03500
(0.93%)
3.80500 USD
A
ALEC
-0.30000
(-4.99%)
5.71000 USD
E
EXAS
12.150
(26.55%)
57.910 USD
G
GH
-1.770
(-5.04%)
33.380 USD
R
RARE
-0.870
(-1.93%)
44.140 USD
R
RGEN
-1.970
(-1.18%)
165.630 USD
S
SAGE
-1.21000
(-11.03%)
9.76000 USD
TTD
-2.100
(-2.34%)
87.780 USD
V
VEEV
-2.870
(-1.50%)
189.050 USD
News

Title: Natera

Sector: Healthcare
Industry: Diagnostics & Research
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.